Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced that the Company will host its annual Research and Development Day on Thursday, July 12, 2012, from 9:00am – 12:00pm (ET) at 215 First Street, Cambridge, MA, 02142.
Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board, will give a seminar on cancer stem cells. Verastem management will give updates on the progress of programs and discuss future plans.
To register to attend the event, please email
or call 617-252-9314.
A live webcast of the event can be accessed by visiting the investors section of the company’s website at
or through the link below. A replay will be available for two weeks from the date of the event.
A live, listen-only conference call of the event can be accessed by dialing 1-866-700-7173 five minutes prior to the start of the event and providing the passcode 73322380.
The details for the annual Research and Development Day are as follows:
215 First Street, Cambridge, MA, 02142
July 12, 2012
9:00am – 12:00pm (ET)
Conference Call Dial-in:
Conference Call Passcode:
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. For more information please visit
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.